Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERISUDD study of rifaximin and mesalazine for symptomatic uncomplicated diverticular disease
2016-004159-56Phase 4Terminated
- Sponsor
- University of Naples Federico II
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin, Salcrozine in Symptomatic uncomplicated diverticular disease (SUDD), sponsored by University of Naples Federico II. Started May 2021; status: terminated.
02
Drugs
rifaximinSalcrozine
03
Conditions
Symptomatic uncomplicated diverticular disease (SUDD)
Beyond the preview
Go deeper on 2016-004159-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004159-56.